

# Ligands to the 2Fe iron-sulfur center in succinate dehydrogenase

Arnthór Ævarsson and Lars Hederstedt

Department of Microbiology, University of Lund, Sölvegatan 21, S-223 62 Lund, Sweden

Received 1 March 1988

Membrane-bound succinate oxidoreductases are flavoenzymes containing one each of a 2Fe, a 3Fe and a 4Fe iron-sulfur center. Amino acid sequence homologies indicate that all three centers are located in the Ip (B) subunit. From polypeptide and gene analysis of *Bacillus subtilis* succinate dehydrogenase-defective mutants combined with earlier EPR spectroscopic data, we show that four conserved cysteine residues in the first half of Ip are the ligands to the [2Fe-2S] center. These four residues have previously been predicted to be the ligands. Our results also suggest that the N-terminal part of *B. subtilis* Ip constitutes a domain which can incorporate separately the 2Fe center and interact with Fp, the flavin-containing subunit of the dehydrogenase.

Structural mutant; Iron-sulfur protein; *sdh* gene; Succinate oxidoreductase; Nonsense mutation; (*B. subtilis*)

## 1. INTRODUCTION

Membrane-bound succinate dehydrogenase (SDH) and fumarate reductase (FRD) are iron-sulfur flavoenzymes (EC 1.3.99.1) which catalyze succinate-fumarate interconversion. Their chemical composition and primary structure are conserved (cf. [1–5]). The catalytic part is a dimer with a 60–79 kDa and a 25–31 kDa protein subunit. One FAD is covalently bound to a histidine in the larger flavoprotein (Fp or A) subunit, whereas three iron-sulfur centers seem to be located in the smaller iron-protein (Ip or B) subunit. Studies mainly with mammalian SDH and *Escherichia coli* FRD have demonstrated the centers to be one [2Fe-2S], one [3Fe-xS] (where x is 3 or 4) and one [4Fe-4S] [1,6–9].

The role of each prosthetic group in electron transfer between the dicarboxylate at the active site on Fp and the electron acceptor/donor component in the membrane is not known in detail [10,11]. Structural information on how the FAD and the iron-sulfur centers are arranged within the enzyme

is required in order to understand fully the assembly and the function of SDH and FRD.

The complete amino acid sequence of Ip is available from *E. coli* FRD [12] and SDH [13], *Bacillus subtilis* SDH [14], bovine heart SDH [15] and *Proteus vulgaris* FRD [16]. They contain 11 (*E. coli* SDH only 10) cysteine residues at conserved positions distributed in three clusters designated I, II and III [1,13]. Based on amino acid sequence comparisons with less complex iron-sulfur proteins of known three-dimensional structure, it has been proposed that the four cysteines of cluster I are ligands to the 2Fe center, whereas clusters II and III would ligate the 3Fe and 4Fe centers [1,17]. Herein we present experimental evidence from *B. subtilis* mutant SDH for the ligation of the 2Fe center to the cysteine residues of cluster I.

The 2Fe, 3Fe and 4Fe centers have been demonstrated in *B. subtilis* SDH and are called S-1, S-3 and S-2, respectively [18,19]. EPR spectroscopy of *B. subtilis* mutants defective in Ip showed that center S-1 can be assembled in soluble SDH, provided that the mutant contained Fp and a fragment of about 15 kDa or larger of Ip [18]. Wild-type Ip has a molecular mass of 28 kDa. From these previous results it could not be unam-

Correspondence address: L. Hederstedt, Department of Microbiology, University of Lund, Sölvegatan 21, S-223 62 Lund, Sweden

biguously concluded whether the Ip fragments in the mutants were truncated polypeptides resulting from nonsense mutations or were proteolytic degradation products from a full-length mutant Ip. We have now analysed Ip polypeptides from four mutants, mapped the respective mutations in the structural gene for Ip, *sdhB*, and identified one mutation by DNA sequence analysis. The results together with previous EPR data show that SDH with a truncated Ip lacking cysteine clusters II and III can still ligate iron-sulfur center S-1.

## 2. MATERIALS AND METHODS

### 2.1. Bacterial strains, plasmids and phages

The origin and Sdh phenotype of *B. subtilis* mutants KA94109 (*sdhC109*, *ilvB2*), KA97083 (*sdhB83*, *trpC2*, *leu-2*), KA99103 (*sdhB103*, *leu-2*), KA97118 (*sdhB118*, *trpC2*, *leu-2*) and KA99123 (*sdhB123*, *leu-2*) have been described in [20]. KA99103 and KA99123 are Trp<sup>+</sup> derivatives of strains KA97103 and KA97123. The *B. subtilis* *sdhC*, *sdhA* and *sdhB* genes encoding cytochrome *b*-558, Fp and Ip were until 1987 designated *sdhA*, *sdhB* and *sdhC*, respectively [14]. *E. coli* JM83 (*ara*,  $\Delta(lac-proAB)$ , *rpsL*,  $\phi 80$ , *lacZ* $\Delta$ M15) [21] and 5K (*hsdR*, *thi*, *thr*, *rpsL*, *lacZ*) [22] were used for plasmid production. *E. coli* JM101 (*supE*, *thi*,  $\Delta(lac-proAB)$ , [F', *traD36*, *proAB*, *lacI*<sup>F</sup> $\Delta$ M15]) and *E. coli* JM103 (*thi*, *rpsL*, *sbcl15*, *endA*, *hspR4*, *supE*,  $\Delta(lac-proAB)$ , [F', *traD36*, *proAB*, *lacI*<sup>F</sup> $\Delta$ M15]) were the hosts for propagation of bacteriophages M13 mp18 and M13 mp19 and recombinants thereof [21].

Plasmids pSH1047 (*sdhC sdhA sdhB gerE*) [23], pSDH412 (*sdhB*) [24] and pUC18 and pUC19 [21] have been described before. pLUW1 is pUC18 into which the 4.5 kbp *sdhAB PstI* fragment of pSH1047 has been inserted. Integration vector pLUW3 is a 6.3 kbp derivative of pNO1523 [25] containing the *kan* gene of pUB110 [26] and a 395 bp *HindIII-PvuII B. subtilis* DNA fragment (ORF2) from the region just downstream of *sdhB* (fig.2).

### 2.2. Growth media and transformation

*E. coli* JM strains and strain 5K were made competent by CaCl<sub>2</sub> treatment [27] and by the method of Hanahan [28], respectively. *B. subtilis* was grown to competence as described by Arwert and Venema [29], except that the cells were grown at 37°C for 4.5 instead of 3.5 h. *E. coli* transformants were selected on LA plates with ampicillin (35 mg/l). *B. subtilis* kanamycin-resistant transformants were selected on tryptose blood agar base (Difco, USA) plates containing kanamycin sulfate (5 mg/l). Sdh<sup>+</sup> transformants were selected on minimal citrate/glutamate plates [30].

### 2.3. In vitro DNA techniques

Plasmid DNA was isolated according to the procedure of Ish-Horowitz and Burke [31]. *B. subtilis* chromosomal DNA was isolated as described for plasmid DNA by Canosi et al. [32]. Restriction endonuclease digestions, agarose gel electrophoresis and ligation with bacteriophage T<sub>4</sub> DNA ligase followed standard methods [33]. DNA fragments were generally isolated

from agarose gels using GeneClean (BIO 101, USA). Propagation of bacteriophage M13 and isolation of single-stranded DNA were carried out according to Messing [34]. DNA sequence analyses were performed using the dideoxy chain-termination method [35] with modified T<sub>7</sub> DNA polymerase [36].

## 3. RESULTS

### 3.1. IP antigen in mutants

*B. subtilis* mutants KA97083, KA99103, KA97118 and KA99123 lack SDH activity, have normal Fp subunits in the cytoplasm and are defective in Ip due to mutations in the *sdhB* gene [20]. With the exception of KA99123, they contain iron-sulfur center S-1 as determined by EPR spectroscopy of cell-free extracts [18]. The mutants and a reference strain KA94109 (mutant with cytoplasmic wild-type Fp and Ip subunits) were analysed with respect to the Ip subunit. Extracts were immunoabsorbed with anti-*Ip* antibodies and the antigens were then run in SDS-polyacrylamide gel electrophoresis (fig.1).

The wild-type Ip from KA94109 appeared as a doublet band with an apparent molecular mass of 28 kDa. Mutants KA99103 and KA97118 contained a distinct single Ip antigen of approx. 16 kDa (fig.1, lanes B,C), whereas KA97083 had an antigen of about 19 kDa (lane E). Strain KA99123 lacked detectable Ip (lane D). Full-length Ip was not found in any of the mutants. A trace of 28 kDa Ip antigen has however been detected in KA99123 cell extracts using immunoblot analysis (Schröder, I., unpublished).

### 3.2. Genetic mapping of *sdhB* mutations

The *sdhB* mutation in each mutant was mapped by transformation with overlapping wild-type *B. subtilis* DNA fragments corresponding to the *sdhB* region of the chromosome. The DNA fragments used and the results of the experiments are shown in fig.2.

Mutations *sdhB103* and *sdhB118* which both result in an about 16 kDa Ip antigen, mapped to a 200 bp *DraI-HindIII* fragment from the middle part of *sdhB*. The two mutations are possibly identical. Mutation *sdhB83* has previously been mapped to a location distal to *sdhB103* [20] and upstream of the *NarI* site at nucleotide 3245 in *sdhB* [37]. The *HindIII* fragment of subclone pSDHB45 carried the wild-type allele of *sdhB83*.




Fig.1. Ip antigens immunoadsorbed from [ $^{35}$ S]methionine-labeled mutant *B. subtilis* cell lysates and analyzed by SDS-polyacrylamide (10–15% acrylamide) gel electrophoresis. An autoradiograph of the gel is shown. Preparation of cell lysates, immunoadsorption using protein A-Sepharose 4B-Cl and electrophoresis were performed as in [14]. A, KA94109 (wild-type Ip); B, KA99103 (*sdhB103*); C, KA97118 (*sdhB118*); D, KA99123 (*sdhB123*); E, KA97083 (*sdhB83*).

From these results we conclude that *sdhB83* is located on an 86 bp fragment flanked by nucleotides 3159 and 3245. Mutation *sdhB123* seems to be located close to the *DraI* site in *sdhB*, because it could only be rescued by DNA with this site intact. Alternatively, *sdhB123* is two mutations, one on each side of the *DraI* site (fig.2).

### 3.3. *sdhB103* is a nonsense mutation

The location of mutation *sdhB103* in the structural gene for the Ip polypeptide and the size of the resulting Ip antigen strongly suggested that a stop codon has been introduced, leading to a truncated gene product. To confirm this and to map the exact location of the mutation we cloned *sdhB* from KA99103 and determined the nucleotide sequence of the mutated DNA fragment. The cloning was performed with the use of integration vector pLUW3 essentially by the same technique as described previously for the isolation of *sdhC* mutant genes [30]. Plasmid pSDHB103 was generated from *EcoRI*-digested KA99103::pLUW3 chromosomal DNA. The plasmid contained the mutant *sdhB* gene and 1 kbp of *sdhA*.




Fig.2. Map of the *sdh* region in *B. subtilis* and mapping of *sdhB* mutations. The DNA fragments shown in the lower part were isolated from pLUW1 or pSDH412 and cloned into pUC18 or pUC19. *B. subtilis* with the indicated *sdhB* mutations was then transformed with saturating amounts of the purified plasmids and *Sdh*<sup>+</sup> transformants were selected (+, transformants; -, no transformants). Relevant endonuclease restriction sites are indicated; D, *DraI*; E, *EcoRI*; H, *HindIII*; N, *NarI*; Pv, *PvuII*. The short arrow just before *sdhC* shows the start-point and direction of transcription of the *sdh* operon.

The 200 bp *DraI*-*HindIII* fragment (see fig.2) of pSDHB103 was subcloned in phage M13 and the complete nucleotide sequence of both strands was determined. Only one base pair change was found compared to the wild-type sequence [14]. The G to A substitution at nucleotide 3113 changes a tryptophan codon to an UGA stop codon. The predicted product from this mutant *sdhB* gene is a truncated Ip polypeptide, 146 amino acid residues long and with a calculated mass of 16841 Da, the initiation methionine excluded [38].

## 4. DISCUSSION

Iron-sulfur centers in proteins are usually ligated to cysteine residues, however, a non-cysteine residue like histidine can also function as a ligand [17,39]. The 2Fe center in succinate oxidoreductases is most likely ligated to four cysteine residues in the Ip subunit.

A successful separation of SDH into Fp and Ip without destruction of the center has not been reported. The ligands to the 2Fe center S-1 have



## REFERENCES

- [1] Ohnishi, T. (1987) *Curr. Top. Bioenerg.* 15, 37–65.
- [2] Hatefi, Y. (1985) *Annu. Rev. Biochem.* 54, 1015–1069.
- [3] Cole, S.T., Condon, C., Lemire, B.D. and Weiner, J.H. (1985) *Biochim. Biophys. Acta* 135, 381–403.
- [4] Burke, J.J., Siedow, J.N. and Moreland, D.E. (1982) *Plant Physiol.* 70, 1577–1581.
- [5] Samain, E., Patil, D.S., DerVartanian, D.V., Albagnac, G. and LeGall, J. (1987) *FEBS Lett.* 216, 140–144.
- [6] Johnson, M.K., Morningstar, J.E., Bennett, D.E., Ackrell, B.A.C. and Kearney, E.B. (1985) *J. Biol. Chem.* 260, 7368–7378.
- [7] Maguire, J.J., Johnson, M.K., Morningstar, J.E., Ackrell, B.A.C. and Kearney, E.B. (1985) *J. Biol. Chem.* 260, 10909–10912.
- [8] Morningstar, J.E., Johnson, M.K., Cecchini, G., Ackrell, B.A.C. and Kearney, E.B. (1985) *J. Biol. Chem.* 260, 13631–13638.
- [9] Cammack, R., Patil, D.S. and Weiner, J.H. (1986) *Biochim. Biophys. Acta* 870, 545–551.
- [10] Cammack, R., Maguire, J.J. and Ackrell, B.A.C. (1988) in: *Cytochrome Systems. Molecular Biology and Bioenergetics* (Papa, S. ed.) Plenum, New York, in press.
- [11] Singer, T.P. and Johnson, M.K. (1985) *FEBS Lett.* 190, 189–198.
- [12] Cole, S.T., Grundström, T., Jaurin, B., Robinson, J.J. and Weiner, J.H. (1982) *Eur. J. Biochem.* 126, 211–216.
- [13] Darlison, M.G. and Guest, J.R. (1984) *Biochem. J.* 223, 507–517.
- [14] Phillips, M.K., Hederstedt, L., Hasnain, S., Rutberg, L. and Guest, J.R. (1987) *J. Bacteriol.* 169, 864–873.
- [15] Yao, Y., Wakabayashi, S., Matsuda, S., Matsubara, H., Yu, L. and Yu, C.-A. (1986) in: *Iron-Sulfur Protein Research* (Matsubara, H. et al. eds) pp.240–244, Springer, Tokyo.
- [16] Cole, S.T. (1987) *Eur. J. Biochem.* 167, 481–488.
- [17] Cammack, R. (1983) *Chem. Scr.* 21, 87–95.
- [18] Hederstedt, L., Maguire, J.J., Waring, A.J. and Ohnishi, T. (1985) *J. Biol. Chem.* 260, 5554–5562.
- [19] Maguire, J.J., Magnusson, K. and Hederstedt, L. (1986) *Biochemistry* 25, 5202–5208.
- [20] Hederstedt, L., Magnusson, K. and Rutberg, L. (1982) *J. Bacteriol.* 152, 157–165.
- [21] Yanisch-Perron, C., Viera, J. and Messing, J. (1985) *Gene* 33, 103–119.
- [22] Hubacek, J. and Glover, S.W. (1970) *J. Mol. Biol.* 50, 111–127.
- [23] Hasnain, S., Sammons, R., Roberts, I. and Thomas, C.M. (1985) *J. Gen. Microbiol.* 131, 2269–2279.
- [24] Fridén, H., Hederstedt, L. and Rutberg, L. (1987) *FEMS Microbiol. Lett.* 41, 203–206.
- [25] Dean, D. (1981) *Gene* 15, 99–102.
- [26] Gryczan, T.J., Contente, S. and Dubnau, D. (1978) *J. Bacteriol.* 134, 318–329.
- [27] Cohen, S.N., Chang, C.Y. and Hsu, L. (1972) *Proc. Natl. Acad. Sci. USA* 69, 2110–2114.
- [28] Hanahan, D. (1983) *J. Mol. Biol.* 166, 557–580.
- [29] Arwert, F. and Venema, G. (1973) *Mol. Gen. Genet.* 123, 185–198.
- [30] Fridén, H., Rutberg, L., Magnusson, K. and Hederstedt, L. (1987) *Eur. J. Biochem.* 168, 695–701.
- [31] Ish-Horowitz, D. and Burke, J.F. (1981) *Nucleic Acids Res.* 9, 2989–2998.
- [32] Canosi, U., Morelli, G. and Trautner, T.A. (1978) *Mol. Gen. Genet.* 166, 259–267.
- [33] Maniatis, T., Fritsch, E.F. and Sambrook, J. (1982) *Molecular Cloning. A Laboratory Manual*, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY.
- [34] Messing, J. (1983) *Methods Enzymol.* 101, 20–78.
- [35] Sanger, F., Nicklen, S. and Coulson, A.R. (1977) *Proc. Natl. Acad. Sci. USA* 74, 5463–5467.
- [36] Tabor, S. and Richardson, C.C. (1987) *Proc. Natl. Acad. Sci. USA* 84, 4767–4771.
- [37] Cutting, S. and Mandelstam, J. (1986) *J. Gen. Microbiol.* 132, 3013–3024.
- [38] Hederstedt, L., Bergman, T. and Jörnvall, H. (1987) *FEBS Lett.* 213, 385–390.
- [39] Cline, J.F., Hoffman, B.M., Mims, W.B., Lattaie, E., Ballou, D.P. and Fee, J.A. (1985) *J. Biol. Chem.* 260, 3251–3254.
- [40] Albracht, S.P.J., Unden, G. and Kröger, A. (1981) *Biochim. Biophys. Acta* 661, 295–302.
- [41] LoBrutto, R., Haley, P.E., Yu, C.-A. and Ohnishi, T. (1987) in: *Advances in Membrane Biochemistry and Bioenergetics* (Kim, C.H. et al. eds) pp.449–559, Plenum, New York.
- [42] Vinogradov, A.D., Ackrell, B.A.C. and Singer, T.P. (1975) *Biochem. Biophys. Res. Commun.* 67, 803–809.